Human Health in Extreme ConditionsNCT07275489
CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands
An observational study of Human Health in Extreme Conditions, run by University Hospital, Angers at 1 site in French Southern and Antarctic Lands.
Trial summary
Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Human Health in Extreme Conditions
- What is being tested?
- blood ponction, urines collection and hair collection
- How many people
- 9 participants
- Where
- 1 siteFrench Southern and Antarctic Lands
- Study dates
- 20 Dec 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol
Who may be able to join
- healthy people aged > 18 years
- Participant affiliated with or benefiting from a social security system
- Participant has signed informed consent
- Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
- Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol
Who cannot join
- age < 18 years
- Pregnant, breastfeeding, or postpartum woman
- immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
- Person refusing to participate in the study
- Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
- Person undergoing involuntary psychiatric treatment
- Person subject to a legal protection measure
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
French Southern and Antarctic Lands1 site, 1 recruiting
- Recruiting
Hôpital SAMUKER, Port-aux-français/ Archipel KERGUELEN /Terres Australes et Antarctiques Françaises
Port-aux-Français, Terres Australes Et Antarctiques Françaises
Marine MEYERBER, MD, 02 62 00 40 33 ext. +5, medecin@ker-taaf.fr
About this study
Official title: Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands
Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.
These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.
Read more
To help fill this gap, the CHOICE Kerguelen 2 study will follow a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen study is conducted in collaboration with the French Polar Institute (IPEV).
The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers at four time points during the time of their confinement on the Kerguelent Islands: tevery three months during their stay. These samples will be than analyzed to characterize the immune profiles and intestinal microbiota of the subjects assess eventual viral reactivations and stress biological markers. These analyses will allow to better understand how the immune system reacts to prolonged isolation, and to identify immune profiles that may develop under prolonged stress and limited social contact.
The long-term aim of this project is not only to improve our understanding of human immunity in extreme environments, but also to inform medical research for people living with chronic illness. By studying healthy individuals placed in physically and mentally challenging environments, scientists can better understand how stress and isolation may weaken immune defenses. The findings may one day help design new approaches to support immune health in vulnerable populations.
- Conditions
- Human Health in Extreme Conditions
- Being tested
- blood ponction, urines collection, hair collection, saliva collection, stools collection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood ponctionOther
blood ponction
urines collectionOther
urines collection
hair collectionOther
hair collection
saliva collectionOther
saliva collection
stools collectionOther
stools collection
| Study group | Role | What they receive |
|---|---|---|
| HD (healthy donors) | Not described Receives: Other: blood ponction; Other: urines collection; Other: hair collection; Other: saliva collection; Other: stools collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
lymphocytes subsets during overwintering on the Kerguelen Islands
lymphocytes subsets by flow cytometry
Measured: At inclusion (3 months after the beginning of overwintering)
lymphocytes subsets during overwintering on the Kerguelen Islands
lymphocytes subsets by flow cytometry
Measured: At 3 months (6 months after the beginning of overwintering )
lymphocytes subsets during overwintering on the Kerguelen Islands
lymphocytes subsets by flow cytometry
Measured: At 6 months (9 months after the beginning of overwintering )
lymphocytes subsets during overwintering on the Kerguelen Islands
lymphocytes subsets by flow cytometry
Measured: At 9 months (12 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands
RNAseq
Measured: At inclusion (3 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands
RNAseq
Measured: At 3 months (6 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands
RNAseq
Measured: At 6 months (9 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands
RNAseq
Measured: At 9 months (12 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands
plasmatic cytokines by Bioplex
Measured: At inclusion (3 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands
plasmatic cytokines by Bioplex
Measured: At 3 months (6 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands
plasmatic cytokines by Bioplex
Measured: At 6 months (9 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands
plasmatic cytokines by Bioplex
Measured: At 9 months (12 months after the beginning of overwintering )
fecal microbiota
fecal microbiota by bacterial sequencing
Measured: At inclusion (3 months after the beginning of overwintering )
fecal microbiota
fecal microbiota by bacterial sequencing
Measured: At 3 months (6 months after the beginning of overwintering )
fecal microbiota
fecal microbiota by bacterial sequencing
Measured: At 6 months (9 months after the beginning of overwintering )
fecal microbiota
fecal microbiota by bacterial sequencing
Measured: At 9 months (12 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
Measured: At inclusion (3 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
Measured: At 3 months (6 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
Measured: At 6 months (9 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
Measured: At 9 months (12 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands
psychological stress by CST test form
Measured: At inclusion (3 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands
psychological stress by CST test form
Measured: At 3 months (6 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands
psychological stress by CST test form
Measured: At 6 months (9 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands
psychological stress by CST test form
Measured: At 9 months (12 months after the beginning of overwintering )
Secondary outcomes (16)
EBV viral reactivations during overwintering on the Kerguelen Islands
EBV in blood and saliva by quantitative PCR
Measured: At inclusion (3 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands
EBV in blood and saliva by quantitative PCR
Measured: At 3 months (6 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands
EBV in blood and saliva by quantitative PCR
Measured: At 6 months (9 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands
EBV in blood and saliva by quantitative PCR
Measured: At 9 months (12 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
CMV in blood and saliva by quantitative PCR
Measured: At inclusion (3 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
CMV in blood and saliva by quantitative PCR
Measured: At 3 months (6 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
CMV in blood and saliva by quantitative PCR
Measured: At 6 months (9 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
CMV in blood and saliva by quantitative PCR
Measured: At 9 months (12 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
HSV in blood and saliva by quantitative PCR
Measured: At inclusion (3 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
HSV in blood and saliva by quantitative PCR
Measured: At 3 months (6 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
HSV in blood and saliva by quantitative PCR
Measured: At 6 months (9 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
HSV in blood and saliva by quantitative PCR
Measured: At 9 months (12 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
TTV viral loads in blood and saliva by quantitative PCR
Measured: At inclusion (3 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
TTV viral loads in blood and saliva by quantitative PCR
Measured: At 3 months (6 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
TTV viral loads in blood and saliva by quantitative PCR
Measured: At 6 months (9 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
TTV viral loads in blood and saliva by quantitative PCR
Measured: At 9 months (12 months after the beginning of overwintering )
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start20 Dec 2025
- Primary completion19 Jan 2026
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Health in Extreme ConditionsStudies of the same condition, open and under way.
- More trials run by University Hospital, AngersThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 9 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Angers
- Sponsor type
- Other government
- Collaborators
- Institut Polaire Français Paul-Emile Victor (IPEV)
- Responsible party
- Sponsor
- Investigators
- Charline MIOT, MD, Principal investigator, University Hospital, Angers
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07275489
- Sponsor's protocol ID
- 49RC25_0439
- Other IDs
- 2025-A02538-41
- Status last verified
- Jun 2026
- First submitted
- 27 Nov 2025
- Last updated
- 15 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands
- ClinicalTrials.gov ID
- NCT07275489
- Acronym / sponsor ID
- 49RC25_0439
- Conditions
- Human Health in Extreme Conditions
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 9 participants (estimated)
- Lead sponsor
- University Hospital, AngersOther government
- Collaborators
- Institut Polaire Français Paul-Emile Victor (IPEV)
- Study start
- 20 Dec 2025 (actual)
- Primary completion
- 19 Jan 2026 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.
These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.
To help fill this gap, the CHOICE Kerguelen 2 study will follow a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen study is conducted in collaboration with the French Polar Institute (IPEV).
The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers at four time points during the time of their confinement on the Kerguelent Islands: tevery three months during their stay. These samples will be than analyzed to characterize the immune profiles and intestinal microbiota of the subjects assess eventual viral reactivations and stress biological markers. These analyses will allow to better understand how the immune system reacts to prolonged isolation, and to identify immune profiles that may develop under prolonged stress and limited social contact.
The long-term aim of this project is not only to improve our understanding of human immunity in extreme environments, but also to inform medical research for people living with chronic illness. By studying healthy individuals placed in physically and mentally challenging environments, scientists can better understand how stress and isolation may weaken immune defenses. The findings may one day help design new approaches to support immune health in vulnerable populations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HD (healthy donors) | – | Other: blood ponction, Other: urines collection, Other: hair collection, Other: saliva collection, Other: stools collection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol
Key inclusion criteria (5 listed)
- healthy people aged > 18 years
- Participant affiliated with or benefiting from a social security system
- Participant has signed informed consent
- Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
- Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol
Key exclusion criteria (7 listed)
- age < 18 years
- Pregnant, breastfeeding, or postpartum woman
- immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
- Person refusing to participate in the study
- Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood ponctionblood ponction | Other | HD (healthy donors) |
| urines collectionurines collection | Other | HD (healthy donors) |
| hair collectionhair collection | Other | HD (healthy donors) |
| saliva collectionsaliva collection | Other | HD (healthy donors) |
| stools collectionstools collection | Other | HD (healthy donors) |
Primary outcome
lymphocytes subsets during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering)
lymphocytes subsets by flow cytometry
lymphocytes subsets during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
lymphocytes subsets by flow cytometry
lymphocytes subsets during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
lymphocytes subsets by flow cytometry
lymphocytes subsets during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
lymphocytes subsets by flow cytometry
RNAsep during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
RNAseq
RNAsep during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
RNAseq
RNAsep during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
RNAseq
RNAsep during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
RNAseq
plasmatic cytokines during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
plasmatic cytokines by Bioplex
plasmatic cytokines during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
plasmatic cytokines by Bioplex
plasmatic cytokines during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
plasmatic cytokines by Bioplex
plasmatic cytokines during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
plasmatic cytokines by Bioplex
fecal microbiota
Time frame: At inclusion (3 months after the beginning of overwintering )
fecal microbiota by bacterial sequencing
fecal microbiota
Time frame: At 3 months (6 months after the beginning of overwintering )
fecal microbiota by bacterial sequencing
fecal microbiota
Time frame: At 6 months (9 months after the beginning of overwintering )
fecal microbiota by bacterial sequencing
fecal microbiota
Time frame: At 9 months (12 months after the beginning of overwintering )
fecal microbiota by bacterial sequencing
hormonal stress markers during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
hormonal stress markers during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
hormonal stress markers during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
hormonal stress markers during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry
stress profile during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
psychological stress by CST test form
stress profile during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
psychological stress by CST test form
stress profile during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
psychological stress by CST test form
stress profile during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
psychological stress by CST test form
16 secondary outcomes
EBV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At inclusion (3 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 3 months (6 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 6 months (9 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands
Time frame: At 9 months (12 months after the beginning of overwintering )
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Individual participant dataSharing planned: Yes. Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
Related trials for Human Health in Extreme Conditions
Active, not recruiting
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
Type 2 Diabetes Mellitus, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charline MIOT, MD principal investigator
University Hospital, Angers
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Health in Extreme Conditions, run by University Hospital, Angers at 1 site in French Southern and Antarctic Lands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in French Southern and Antarctic Lands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charline MIOT, MD (02 41 35 36 37 ext. +33, chmiot@chu-angers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
lymphocytes subsets during overwintering on the Kerguelen Islands (time frame: At inclusion (3 months after the beginning of overwintering)). The study lists 24 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.